Massachusetts Society of Clinical Oncologists - FDA Approved osimertinib (Tagrisso) for treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approved osimertinib (Tagrisso) for treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations

FDA Approved osimertinib (Tagrisso) for treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations

29 Jun 2018 8:30 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration osimertinib (Tagrisso; AstraZeneca) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org